Exploring the role of O-Mannosylation in the modulation of E-Cadherin function in Gastric Cancer cell line models by Oliveira, Tiago Manuel Fontes
  
Universidade do Minho 
Escola de Ciências 
 
 
 
Tiago Manuel Fontes Oliveira 
 
Exploring the role of O-Mannosylation in 
the modulation of E-Cadherin function in 
Gastric Cancer cell line models 
 
 
 
 
Tese de Mestrado 
Mestrado em Bioquímica Aplicada – Biomedicina 
 
Trabalho efectuado sob a orientação da 
Professora Doutora Salomé S. Pinho 
 
 
 
Setembro 2015 
 DECLARAÇÃO 
 
 
Nome 
_____________________________________________________________________________________ 
Endereço electrónico: _____________________________ Telefone: _______________  / _______________ 
Número do Bilhete de Identidade: ______________________  
Título dissertação □/tese □ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
Orientador(es): 
_____________________________________________________________________________________ 
____________________________________________________   Ano de conclusão: ___________ 
Designação do Mestrado ou do Ramo de Conhecimento do Doutoramento: 
_____________________________________________________________________________________ 
 
 
Nos exemplares das teses de doutoramento ou de mestrado ou de outros trabalhos entregues para 
prestação de provas públicas nas universidades ou outros estabelecimentos de ensino, e dos quais é 
obrigatoriamente enviado um exemplar para depósito legal na Biblioteca Nacional e, pelo menos outro 
para a biblioteca da universidade respectiva, deve constar uma das seguintes declarações: 
 
1. É AUTORIZADA A REPRODUÇÃO INTEGRAL DESTA TESE/TRABALHO APENAS PARA EFEITOS 
DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE 
COMPROMETE; 
 
2. É AUTORIZADA A REPRODUÇÃO PARCIAL DESTA TESE/TRABALHO (indicar, caso tal seja 
necessário, nº máximo de páginas, ilustrações, gráficos, etc.), APENAS PARA EFEITOS DE 
INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE 
COMPROMETE; 
 
3. DE ACORDO COM A LEGISLAÇÃO EM VIGOR, NÃO É PERMITIDA A REPRODUÇÃO DE 
QUALQUER PARTE DESTA TESE/TRABALHO 
 
 
 
 
Universidade do Minho,  ___/___/______ 
 
 
Assinatura: ________________________________________________ 
  
  
i 
Agradecimentos 
 
Em primeiro lugar gostaria de agradecer à Professora Salomé e ao Professor Celso 
Reis por me terem permitido colaborar no grupo “Glycobiology in Cancer”, bem como 
a todos os que me ajudaram a crescer profissional e pessoalmente no instituto. 
Obrigado a toda a gente do IPATIMUP que esteve ao meu lado a cumprir esta etapa. 
Vocês são boa gente. Desejo-vos o melhor. Stefan, I cannot let this pass. You are one of 
the brightest guys I know. I wish you all the best! And maybe we will work together in 
the future, who knows… 
Um obrigado ao Professor Pedro pelo apoio que veio de Braga, sempre disponível. 
 
Para o meu pessoal da Bioquímica, deixo nesta tese a alma do bioquímico 
FCUP/ICBAS. Viais, Escuta, Márcio, Lau, Melo, Tiago… Vocês são os maiores! Que 
tenham a maior sorte do mundo, sempre.  
Ao meu grande Batista e à sua Tati, obrigado pelos cafés, confidências, cinemas, 
jantares, copos,… Valar Morghulis.  
 
Para a Ana, que me atura todos os dias, a chover, a fazer sol, a rir, a chorar, o maior 
dos obrigados. Seria incapaz de tudo isto sem ti. A verdade é que existe sempre uma 
grande mulher à beira de um grande homem, pelo que, a receber algum crédito por 
este trabalho, terei sempre que o dividir contigo. Ajudaste-me a descobrir quem sou e 
o que quero para mim. És uma verdadeira singularidade na vida de alguém. Tenho a 
maior sorte do mundo. 
À minha família que acredita no que sou e como sou.  
À minha avó.  
  
ii 
 
 
  
 
 
  
  
iii 
RESUMO 
A acção do complexo E-Caderina (E-Cad)-cateninas para a formação de junções 
aderentes estáveis é essencial para a arquitectura de tecidos epiteliais e para a sua 
integridade mecânica, contribuindo de forma preponderante para a supressão 
tumoral. Assim, a disfunção da E-Cad está geralmente associada com a perda das 
propriedades de adesão das células epiteliais, com a capacidade de invasão, e com 
metastização. Como a E-Cad é uma glicoproteína, ela pode ser modificada por N- ou 
por O-glicanos, especificamente por glicanos O-manose (O-Man). A N-glicosilação e a 
O-manosilação iniciam-se no retículo endoplasmático (ER), seguindo para o complexo 
de Golgi, e terminando quando a glicoproteína é libertada no citoplasma ou em 
vesículas para ser transportada para a membrana celular. Os monossacáridos iniciais 
podem ser estendidos em diversos compartimentos do complexo de Golgi por acção 
de diversas glicosiltransferases: no caso da N-glicosilação, as N-
acetilglucosaminiltransferases (GnTs) III e V (GnT-III e GnT-V) estão regularmente 
envolvidas na modificação da estrutura do glicano pela adição de um resíduo de N-
acetilglucosamina (GlcNAc) bisecting ou β-1,6 GlcNAc branching, respectivamente. 
Enquanto a formação de N-glicanos com bisecting GlcNAc por acção da GnT-III leva à 
supressão tumoral, elevados níveis de N-glicanos β-1,6 GlcNAc branching formados por 
acção da GnT-V são geralmente associados a tumores altamente metastáticos. 
Trabalhos prévios do nosso grupo permitiram descrever o impacto da actividade 
destas duas enzimas na expressão e regulação da E-Cad, especificamente num 
contexto de cancro gástrico (GC) que não pode ser explicado apenas devido a 
alterações genéticas e epigenéticas. Recentemente, a O-manosilação ganhou um novo 
interesse quando relacionada com a E-Cad, uma vez que foram descritos diversos 
locais de O-manosilação disponíveis na E-Cad, e que os glicanos O-Man presentes na E-
Cad contribuem para as suas funções biológicas, nomeadamente para a adesão célula-
célula.  
Este trabalho pretende compreender o papel da O-manosilação na modulação das 
funções da E-Cad num contexto de desenvolvimento e progressão tumoral, bem como 
perceber qual a relação, neste contexto, entre a O-manosilação e a N-glicosilação. Os 
resultados obtidos indicam claramente que o aumento de diferenciação de uma linha 
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celular é acompanhado por um aumento no perfil geral de O-manosilação na célula, e 
que a E-Cad apresenta níveis mais elevados de glicanos O-Man ligados nesse caso. Por 
outro lado, observamos que o aumento de glicanos O-Man e a diminuição de glicanos 
GlcNAc branched ligados à E-Cad está relacionado com um fenótipo mais estável. 
Estes resultados apoiam o conceito de que a O-manosilação da E-Cad é essencial 
para as suas funções biológicas, e que a ausência desta modificação pós-traducional 
(PTM) pode ser um dos factores chave para a perda de função desta glicoproteína, o 
que leva ao desenvolvimento e progressão tumoral. De modo global, o objectivo 
principal deste projecto é clarificar ainda mais os mecanismos moleculares que 
conduzem à disfunção da E-Cad no GC e que são fundamentais para o estabelecimento 
de adenocarcinomas humanos, tendo em vista potenciais novas aplicações na cliníca. 
 
 
O trabalho aqui apresentado foi desenvolvido como parte integrante de um 
projecto que visa explorar o perfil de O-manosilação da E-Caderina no cancro gástrico, 
tendo sido desenvolvido por mim e pela Sandra Carvalho (Estudante de Doutoramento 
que co-orientou este trabalho), culminando com a preparação de um artigo para ser 
submetido para publicação. 
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ABSTRACT 
 
The establishment of stable adherens junctions by the action of the E-Cadherin (E-
Cad)-catenins complex is essential for epithelial tissue architecture and mechanical 
integrity, contributing effectively for tumor suppression. Therefore, E-Cad impairment 
is often associated with loss of adhesive properties of epithelial cells, invasiveness and 
metastasis. As E-Cad is a glycoprotein, it can be modified by N- and O-glycans, 
specifically O-mannose (O-Man) glycans. N-glycosylation and O-mannosylation initiate 
at the endoplasmic reticulum (ER), carry on in the Golgi compartment, and terminate 
when the glycoprotein is released to the cytoplasm or liberated in vesicles for the 
cellular membrane. The initial monosaccharide residues can be further extended in the 
several compartments of the Golgi apparatus by the action of several 
glycosyltransferases: in the case of N-glycosylation, N-acetylglucosamyniltransferases 
(GnTs) III and V (GnT-III and GnT-V) are often involved in the modification of the glycan 
structure by the addition of a bisecting N-acetylglucosamine (GlcNAc) or β-1,6 GlcNAc 
branching residue, respectively. While the formation of bisecting GlcNAc N-glycans by 
GnT-III has been proven to be tumor suppressor, high levels of β-1,6 GlcNAc branching 
N-glycans formed by the action of GnT-V are usually associated with highly metastatic 
tumors. Work by our group allowed us to describe the impact of the activity of these 
two enzymes in E-Cad expression and regulation, specifically in a gastric cancer (GC) 
context that cannot be explained solely by genetic or epigenetic alterations. Recently, 
O-mannosylation gained interest relating to E-Cad, as it was described that E-Cad 
presents several available O-mannosylation sites, and that the O-Man glycans present 
on E-Cad contribute to its biological functions, namely cell-cell adhesion.  
This work aims to understand how O-mannosylation modulates E-Cad functions in 
tumor development and progression, and to figure out the interplay between O-
mannosylation and N-glycosylation in this context. Our results clearly indicate that the 
gaining of differentiation status of a cell line is accompanied by an increase in the 
cellular overall O-mannosylation profile, and that E-Cad presents higher levels of O-
Man glycans attached to it in that case. On the other hand, we observed that the 
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increase in O-Man glycans and the decrease of branched GlcNAc N-glycans attached to 
E-Cad is related to a more stable phenotype. 
These results support the idea that O-mannosylation of E-Cad is essential for its 
biological functions, and that the absence of this post-translational modification (PTM) 
may be one of the key elements for the impairment of this glycoprotein, which leads to 
tumor development and progression. Globally, the main goal of this project is to 
further clarify the molecular mechanisms behind E-Cad dysfunction in GC that are 
important in the setting up of human adenocarcinomas, having in mind potential new 
applications in the clinic. 
 
 
The work that is present here was developed as part of a comprehensive project 
that aims to explore the O-mannosylation profile of E-Cadherin in Gastric Cancer, 
carried out by me and Sandra Carvalho (PhD Student that co-supervised this work), 
which will culminate in the preparation of a manuscript to be submitted for 
publication. 
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1.1 Gastric Cancer 
 
According to 2012 GLOBOCAN assessments, Gastric Cancer (GC) was the fifth most 
commonly diagnosed cancer-related malignancy worldwide and the third most 
common cause for cancer-related death in both sexes (Figure 1)1,2. Despite the fact 
that the incidence of 
GC has been declining 
over the past few 
decades, an increase in 
the total number of 
cases is expected due 
to the ageing 
population3. Focusing 
on Portugal statistics, 
GC takes the fifth place 
when accounting to 
overall incidence, and 
the third when 
considering the 
mortality rate2. 
However, GC presents a high incidence to mortality rate when compared to all other 
types of cancers, being supplanted only by lung cancer. 
As GC is a complex and heterogeneous disease displaying different types of 
phenotypes, several methods were proposed to categorize its specific subtypes, 
namely the World Health Organization (WHO) and the Laurén classifications4-6. In 
September 2014 The Cancer Genome Atlas (TCGA) Research Network described a 
whole new way to classify GC into four distinct groups, taking into account its 
molecular characteristics, specifically: Epstein–Barr virus (EBV)-positive, microsatellite 
unstable (MSI), genomically stable (GS), and chromosomally unstable (CIN)7. However, 
the Laurén method is still the most described in the large majority of the publications 
and the most widely used by clinicians. 
Figure 1 - Overall cancer incidence and mortality estimates worldwide in 
2012, according to GLOBOCAN
2
. 
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According to Laurén classification, GC can be sub-divided in two major histological 
types (according to microscopic morphology of the tumor itself), the Intestinal and the 
Diffuse types4. The Intestinal type comprehends between 60 to 70% of the total 
number of GC cases3,6 and is characterized by the formation of autonomous tumors of 
glandular structure. Several risk factors are associated with this subtype of GC, for 
example Helicobacter pylori (H. pylori) infection. H. pylori has a central role in different 
stages of the precancerous processes that culminate in GC, the so-called Correa 
Cascade3,8. Sporadic Intestinal GCs are also usually associated with loss-of-function 
mutations in the adenomatous polyposis coli (APC) gene and gain-of-function 
mutations in the CTNNB1 gene (that codifies β-catenin), which results in an increased 
signaling via the Wnt pathway9. In contrast to the Intestinal type, Diffuse GC, which 
comprehends near 30% of GC cases, is characterized by the loss of cohesion between 
cells and the invasion of the gastric wall by individually infiltrating neoplastic cells 
(Figure 2). The development of Diffuse GC and the precise carcinogenic process is still 
Figure 2 - Clinicopathological profiles of Diffuse and Intestinal Gastric Cancer
11
. 
  
5 
debatable, and occurs in the corpus and fundus portions of the stomach5. Diffuse GC 
can also occur due to hereditary conditions associated to genetic abnormalities, 
namely loss-of-function mutations in the tumor suppressor gene CDH1, which encodes 
for the cell-cell adhesion protein E-Cadherin (E-Cad)10,11. As a matter of fact, these 
mutations in the CDH1 gene also occur sporadically, which means that loss of E-Cad 
seems to be a key event in the development of Diffuse GC12.  
Due to their specific phenotypical characteristics, GCs of the Diffuse sub-type are 
usually diagnosed at latter stages than Intestinal GCs. Usually for both types of GC, 
surgical resection provides the best approach for effectively remove the tumor. 
However, late diagnosis presents a problem for the patient, as tumors become very 
advanced and unresectable. At that time, chemotherapy is the main therapeutic 
option available, but the five year survival rate drops sharply, with patients surviving 
usually less than one year. Even though significant efforts are being made in order to 
improve the therapeutics and surgical approaches, the identification of precise 
molecular mechanisms and biomarkers is urgently needed to improve early diagnosis, 
prognosis and for the development of new therapeutic strategies3,13,14. 
 
1.2 E-Cadherin at the adherens junctions: the importance in 
cell-cell adhesion 
 
The role of E-Cad in cell-cell adhesion molecule and the importance of calcium 
(Ca2+) in this process was first described in 1977 by Masatoshi Takeichi15. The protein 
itself was only described in 1980 by François Jacob and his group16, and it was only one 
year later, in a subsequent work by the same group, that they named it “uvomorulin”, 
due to its role in embryogenesis17. In 1984, Takeichi et al. proposed that the molecules 
responsible for cell-cell adhesion with the dependence of Ca2+, should be named 
“cadherins”  in a more wide-ranging manner, as an alternative to “uvomorulin”, as 
they hypothesized that these molecules were present in a diversity of differentiated 
epithelial cells, instead of being specific of early embryonic cells18. Two years later, 
Takeichi’s group distinguished clearly two individual members of the cadherin family, 
E-Cad (“E” stands for epithelial) and N-Cad (“N” stands for neural)19.  
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E-Cad is a type I cadherin, and is considered to be the prototype of all cadherins due 
to the fact that it was the first protein from this family that was identified, and to all 
the efforts that were made for its characterization, which allowed a better 
understanding of the molecular behavior of E-Cad both in a normal and in a 
pathological condition. The gene which encodes for human E-Cad, CDH1, is located in 
chromosome 16q22.1, and it was first cloned by Berx et al. in 199520, which led to 
subsequent studies regarding the gene activation and silencing (reviewed in 21). It is 
interesting to know that Takeichi et al. were the first ones to be successful in the 
attempt to clone E-Cad cDNA (despite it being mouse’s cDNA22) observing profound 
alterations on the adhesive properties of the transfected cells. Moreover, the same 
authors predicted the importance of the E-Cad propeptide (formed by approximately 
130 aminoacid (aa.) residues) as a short signal sequence for the import of the E-Cad 
precursor to the ER, as well as the length of E-Cad itself, which was estimated to be 
728 aa. residues long, comprising a short cytoplasmic domain (151 aa.), a single 
transmembrane segment (26 aa.) and a large extracellular domain (551 aa.).  
The extracellular domain is composed by five cadherin sub-domains (ECs) (EC1 to 
EC5). These ECs present on cadherins are sequences of 110 aa. residues, and are a key 
element for the classification of this family of proteins. In E-Cad, EC1 is the domain that 
is responsible for the Ca2+-dependent homophilic interactions between two cadherin 
molecules of adjacent cells, which is the reason why it is called the “strand swapping 
domain”. The normal conformation of E-Cad is only attained in the presence of Ca2+ in 
the surrounding microenvironment, which is endorsed with the fact that the Ca2+-
binding domains are extremely well conserved aa. sequences23. The other four 
domains (ECs 2-5) are called the “non-swapping cadherin domains”. EC5 is the domain 
closest to the transmembrane span, and its structure is distinct from the other E-Cad 
ECs, as it is characterized by the presence of additional four conserved cysteine (Cys) 
residues, which have an effect in the formation of strong cell-cell contacts24. 
Moreover, E-Cad has four possible N-glycosylation sites, two on EC4 (Asn554 and 
Asn566) and two on EC5 (Asn618 and Asn633)25, that are of crucial importance when 
considering E-Cad folding26 and cell-cell adhesion function27. 
The cytoplasmic domain of E-Cad interacts with different types of catenins, namely 
α-, β- and p120-catenin. p120-catenin has central role in the maintenance of E-Cad at 
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the cell membrane, but it also influences the cytoskeleton organization, cell signaling 
processes and transcriptional regulation28. β-catenin is also a central molecule in the 
cytoskeleton organization, as it is the intermediate molecule between the cytoplasmic 
domain of E-Cad and α-catenin, which in turn is the responsible for the interaction 
with the actin cytoskeleton itself29(Figure 3). 
E-Cad has been 
extensively described as a 
key molecule in the 
maintenance of tissue 
architecture and 
homeostasis, by allowing 
correct epithelial cell-cell 
adhesion. In order to do 
so, E-Cad molecules form 
cis- and trans- homophilic 
interactions: trans- 
homophilic contacts occur 
when two E-Cad 
molecules from two 
different cells establish an 
adhesive interaction 
between their EC1s, 
forming zipper-like 
structures, while cis- 
interactions are 
established by E-Cad 
molecules in the same cell. The trans- and cis- complexes interact between themselves 
and with the catenins-actin complex in order to form mechanically stable E-Cad 
clusters at the adherens junctions, inhibiting cell motility and providing strong and 
normal associations between cells29,30. 
Several mechanisms have been described to underlie E-Cad dysregulation. Genetic 
alterations (for example, the loss of exons 8 or 9) of the CDH1 gene were associated 
Figure 3 - The E-Cadherin-catenin complex (calcium ions are not 
represented). Interaction with the actin cytosketelon occurs via α-catenin. 
The possible N-glycosylation sites existent in E-Cadherin (Asn554, Asn566, 
Asn618 and Asn633) are here represented as the initial GlcNAc 
monosaccharide. 
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with absence of a wild type (WT) E-Cad, with decreased cell-cell adhesion and 
increased cellular motility31-37. Epigenetic events, specifically hypermethylation in a 
CpG island of one 5’-CDH1 promoter38, are observable in several types of carcinomas 
and are have also been associated with loss of E-Cad gene expression. MicroRNAs 
(miR), such as members of the miR-200 family also regulate CDH1 expression by 
targeting transcriptional repressors (in this case, ZEB1 and ZEB2)39. All the alterations 
leading to decreased E-Cad mRNA expression and protein levels are usually associated 
with loss of cell-cell adhesion and a new capacity of epithelial cells to invade and 
metastasize, hence a poor clinical outcome 40,41. The functional loss of E-Cad is one of 
the best characterized molecular alterations during tumor progression of carcinoma 
cells (cancer cells arising from epithelial tissues), as emphasized by Hanahan and 
Weinberg in “Hallmarks of Cancer: The Next Generation”42. Moreover, there is a 
myriad of transcriptional repressors that act frequently on E-Cad promoter (for 
example, Snail, Slug and Twist21), that are specifically expressed at the invasive front of 
human cancers and are highly regulated by pathways that promote tumor progression, 
such as Wnt and TGF-β43. The protein levels of E-Cad can also be altered due to the 
action of several receptor tyrosine-kinases (RTKs), such as the endothelial growth 
factor recetor (EGFR) or the insulin-like growth factor I receptor (IGF-IR), that 
phosphorylate E-Cad, ultimately resulting in its ubiquitylation by Hakai ligase (and 
subsequent protein degradation)43-45.  
All these types of alterations can be considered major causes of E-Cad dysfunction 
in GC41. Nevertheless, a significant percentage of GC patients harboring E-Cad 
dysfunction cannot be explained solely at the genetic or epigenetic levels46,47. Several 
studies have been pointing towards the impact of glycosylation alterations in the 
regulation of E-Cad in this disease context, as there are several cases that cannot be 
explained solely by genetic or epigenetic mechanisms3. The importance of these post-
translational modifications (PTMs) in GC will be further addressed later.  
 
1.3 Protein Glycosylation 
 
Life as we know it cannot be explained solely by the flux of information from DNA to 
RNA and from RNA to proteins. Proteins can be modified in a wide variety of manners 
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by a wide variety of molecules, resulting in the huge biological complexity observed. 
Glycosylation is a universal process of the majority of eukaryotic cells and one of the 
most frequent occurring PTM, especially when considering transmembrane proteins, 
since their associated glycans contribute to numerous biological functions, such as cell 
adhesion, molecular trafficking, signal transduction pathways and endocytosis48-51. 
Glycans exist as the product of covalent attachment of carbohydrate structures, such 
as oligo- and polysaccharides, to proteins, lipids, carbohydrates or other organic 
compounds, and can be categorized in several different families of glycoconjugates 
(Figure 4). The attachment reaction is catalyzed by specific glycosyltransferases that 
use a specific set of sugars as donor substrates52. There are several types of glycans 
linked to proteins, and the vast majority of those are either N- or O-linked glycans50. N-
glycosylation is characterized by the addition of oligosaccharides to asparagine(Asn) 
residues of the proteins, in a consensus sequence Asn-X-serine(Ser)/threonine(Thr), 
with X being any aa. other than proline(Pro)53,54, while in O-glycosylation the 
attachment reaction occurs in hydroxyl groups of either Ser or Thr residues55,56.  
Figure 4 - Major classes of mammalian glycoconjugates. 
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1.3.1 N-glycosylation 
 
N-glycosylation (Figure 5) is initiated at the endoplasmic reticulum (ER) membrane 
where dolichol phosphate (Dol-Pi) located on the cytoplasmic side of the ER functions 
as a membrane anchor to the formation of the oligosaccharide structure composed by 
two N-acetylglucosamine (GlcNAc) and five mannose (Man) residues, Dol-Pi-Pi-
GlcNAc2Man5. Subsequently, this oligosaccharide structure is flipped to the luminal 
side of the ER membrane, where four Man and three glucose (Glc) residues are added. 
This lipid-linked oligosaccharide precursor is then transferred to an Asn residue of a 
polypeptide chain, that is being translated and arising from the translocon, by the 
action of oligosaccharyltransferase (OST) enzyme complex50,57,58, which is why N-
glycosylation is considered a co- and post-translational modification (CPTM). It is 
noteworthy that GlcNAc2Man9Glc3 acts as a ligand for chaperones from the lectin 
family such as calnexin and calreticulin, and that the complex formed has a role in 
protein quality control and folding (the calnexin/calreticulin cycle)58. In that process, 
the Glc residues and one Man residue are removed in the ER by the action of 
glycosidase II and mannosidase, respectively. The glycoprotein can then continue to 
the Golgi or be degraded, with its fate depending essentially on its N-glycosylation and 
folding status59. In the cis compartment of the Golgi apparatus it is common that 
additional Man residues are removed from the glycoprotein, yielding a GlcNAc2Man5 
glycan linked to the Asn residue. This is the main oligosaccharide structure that allows 
the sequential action of several N-acetylglucosamyniltransferases (GnTs) and 
glycosidases, resulting in the formation of a complex N-glycan. This assembly can then 
be further modified and extended by the addition of sugar residues such as GlcNAc, 
galactose (Gal), fucose (Fuc), Glc, and sialic acid(Neu5Ac). There is still a possibility of 
degradation of badly constructed structures at the trans-Golgi, especially the Man-6-Pi-
Receptor delivers a largely mannosylated N-glycan for the endosomes. Usually 
however, the final structure is moved from the trans-Golgi compartment to vesicles in 
order to be specifically delivered to the cellular membrane – in the case of 
transmembrane proteins such as E-Cad – or to be secreted49,50,54. 
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Figure 5 - N-glycosylation process occurs in the endoplasmic reticulum and the Golgi compartment. The 
synthesis of the Dol-Pi-Pi-GlcNAc2Man9Glc3 structure is necessary for the action of oligosaccharyltransferase (OST) 
that transfers the glycan from the activated dolichol carrier to the protein. The protein can then be folded 
correctly and go to the Golgi compartment, or targeted for degradation. In the Golgi, the action of several 
glycosyltransferases and glycosidases determines the final glycoprotein that is formed. 
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1.3.2 O-glycosylation 
 
The most common example of an O-glycosylated glycoprotein is the mucin, which 
has several N-acetylgalactosamine (GalNAc) monosaccharides covalently α-linked to 
several Ser and Thr residues in tandem repeats. This O-glycosidic bond formation is 
controlled by a member of the UDPGalNAc-polypeptide N-
acetylgalactosaminyltransferase (GalNAc-T) family60,61. This GalNAc residue can then 
be further extended with several monosaccharides such as Gal, GlcNAc, Fuc and 
Neu5Ac (whereas Man and Glc, for example, are not present in mucin-type O-glycans 
at all). This extension process occurs with the action of several distinct 
glycosyltransferases (for example, Core 1 Gal-transferase [C1GalT1] and Core 2 β1-6 N-
acetylglucosaminyltransferase [C2GnT]) and originates eight O-GalNAc glycan core 
structures: cores 1 to 4 are the so-called common cores, and cores 5 to 8 are the 
additional cores61,62. There are several other types of O-glycosylation, namely, O-
mannosylation, O-GlcNAcylation, and O-fucosylation. For the purpose of the present 
work, only O-mannosylation will be further explored.  
 
1.3.3 O-mannosylation 
 
Protein O-mannosylation (Figure 6) consists in the covalent linkage of Man to Ser or 
Thr residues of nascent proteins, and that is the reason why it is considered, as N-
glycosylation, a CPTM63. This process begins in the cytosolic face of the ER with the 
synthesis of Dol-Pi-Man from Dol-Pi and GDP-Man. The produced Dol-Pi-Man is then 
flipped to the luminal side of the organelle, where the action of enzymes from the 
protein O-mannosyltransferase family - POMT in mammalian organisms, PMT in yeast 
(for example) - takes place. These enzymes are responsible for the transference of the 
Man monosaccharide from the activated lipid donor to the nascent protein, with the 
inversion of the anomeric configuration of the Man residue added (leading to the 
formation of an α-D-mannosidic linkage). In mammalian organisms, it seems that the 
two most important POMTs are POMT1 and POMT2, and that POMT1 and POMT2 
genes coexpression is necessary in order to achieve the intended enzymatic activity64. 
This O-Man can then be elongated in the Golgi apparatus with a GlcNAc 
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monosaccharide, in a reaction catalyzed by glycosyltransferases such as protein O-
linked-mannose β-1,2-N-acetylglucosaminyltransferase 1 (POMGnT1)65, Manα1-O- 
Ser/Thr β1,4GlcNAc-transferase (POMGnT2) or GnT-IX (also known as GnT-Vb). These 
Figure 6 - O-mannosylation process initiates in the endoplasmic reticulum by the action of POMT1 or POMT2 
that transfer a mannose residue to a nascent protein. The consequent action of several glycosyltransferases 
determines the type of structure that is formed. O-mannosyl glycans can be divided in cores M1, M2 and M3, 
according to the type of linkage between the mannose and the GlcNAc residues (adapted from 
34
). 
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enzymes do not have, however, a redundant purpose, as the linkage between the 
GlcNAc and Man sugar residues is not the same, which in turn allows the formation of 
several O-Man-glycans, divided from cores M1 to M3 (Figure 6). This nomenclature to 
the set of core O-Man structures was first proposed in 2013 in a publication from the 
Campbell laboratory66, and revised by Jeremy Praissman and Lance Wells in 201467, in 
order to approximate to the one that is accepted for O-GalNac glycans. It is also worth 
mentioning that not all these enzymes have been observed in every tissue studied, 
which can possibly imply a tissue-specific O-mannosylation pattern67. 
This core structures can then be extended by the addition of a variety of 
monosaccharides, such as Gal, Neu5Ac, Fuc or glucuronic acid (GlcA). At least 23 
different O-Man glycan structures have been described by now, the majority of which 
were detected in mammalian brain tissue67-70. The constant improvements of glycomic 
and glycoproteomic technologies will be of huge impact in the attempt to unravel 
novel O-Man structures that can, for instance, be used as important biomarkers.   
 
1.4 Glycosylation in gastric cancer: the importance of N-
glycosylation of E-Cadherin in a gastric cancer context 
 
Glycans have a particular significance in cell biology when considering the cell-
extracellular matrix (ECM) interactions, cell-cell adhesion, cell signaling and 
communication, and in the immune system (Figure 7)51,71. It is well known that 
aberrant glycosylation occurs in all types of cancer, and that there are many specific 
glycosyl epitopes that constitute the tumor associated antigens (TAA), used often as 
biomarkers for cancer detection72-74. Alterations in the N-glycosylation pattern of cell-
cell adhesion molecules such as cadherins3,25,27,75,76 have been correlated with cancer 
invasion and metastasis.  
The frequent dysfunction of E-Cad expression observed in Diffuse-type GC patients 
was observed by Joo et al. in 200246. In effect, this decreased expression was found at 
earlier stages of Diffuse GC, while in the Intestinal subtype the alteration occurs 
typically at later stages. Moreover, when the alteration on E-Cad expression is 
observed in any sub-type of GC, it is usually associated with a poor prognosis for the 
  
15 
patient3. It has been described that approximately 70% of GC cases present any 
structural alteration in CDH1 gene, but rather a delocalization of E-Cad from the cell 
membrane to the cytoplasm47, which suggests that other mechanisms rather than 
genetic or epigenetic are regulating E-Cad functions in cancer77,78. 
It is now widely accepted the fundamental role of glycosylation (particularly N-
glycosylation) in the correct molecular organization of E-Cad in the adherens 
junctions76, as well as its impact in the process of E-Cad expression, and in the 
modulation of its biological functions27,79. As previously referred, E-Cad has four 
potential N-glycosylation sites, two in EC4 and two in EC5. The N-glycans that are 
attached to E-Cad depend on an intricate network of enzymes (glycosyltransferases) 
giving rise to different glycans depending on the tissue type and the physiopathological 
context. The effect of the different glycans on E-Cad activity has been demonstrated, 
for example, by the enzymatic competition between the N-
acetylglucosaminyltransferase-III and N-acetylglucosaminyltransferase-V (GnT-III/GnT-
V) glycosyltransferases. GnT-III is encoded by the MGAT3 gene, and is responsible for 
the addition of a GlcNAc residue via β-1,4 linkage to the central Man of the [Asn]-
GlcNAc2Man3(GlcNAc2) core structure, while GnT-V, encoded by the MGAT5 gene, adds 
Figure 7 - The importance of glycosylation in the formation of a primary tumor and in the metastatic process. 
Glycans are important in the cell-cell adhesion process, in cell-extracellular matrix interactions, as well as in 
several other processes. 
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GlcNAc via β-1,6 linkage to an external α6-Man80. GnT-III is considered of vital 
importance in N-glycan biosynthesis, as its action precedes that of GnT-V. Therefore, 
the bisected oligosaccharide cannot be used as a substrate by GnT-V, precluding the 
synthesis of branching structures81,82.  
In highly metastatic tumors, it is common to observe an increased activity of GnT-V 
and, consequently, an increased expression of β-1,6 GlcNAc branching N-glycan 
structures83. On the other hand, when GnT-V is not present (i.e. MGAT5-knockout 
mice) cancer metastasis is suppressed in a noticeable manner84. GnT-III has been 
described to exhibit an enzymatic priority, which contributes to the suppression of 
cancer metastasis by increasing the number of bisecting GlcNAc structures and, at the 
same time, by impeding the formation of branching GlcNAc structures85. In addition, 
an improvement in the cell-cell adhesion was documented when GnT-III was being 
expressed, as a result of an E-Cad arrest at the cell membrane and delayed turnover75. 
In 2008, the influence of the E-Cad-catenin complex on GnT-III expression was 
determined, suggesting that this complex may act as an inductor of GnT-III expression, 
which in turn allows the formation of bisected GlcNAc N-glycans77. The relationship 
between E-Cad overexpression and the inhibition of the RTKs IGF-IR and the insulin 
receptor (IR) was described by our group using MDA-MD-435 cancer cell line (that 
endogenously does not express E-Cad at the mRNA or protein levels)86, where 
stimulation of these cells with insulin or insulin-like growth factor I (IGF-I) induced a 
decrease in the quantity of bisecting GlcNAc N-glycans (in general and attached to E-
Cad), that was accompanied by delocalization of E-Cad to the cytoplasm and with an 
alteration to a more fibroblastoid-like appearance86. Furthermore, Pierce et al. 
determined that the action of GnT-V on N-Cad’s EC2 and EC3 contributed to a decrease 
of homotopic cell-cell interactions and to the decrease of several intracellular (outside-
in signaling) pathways also involved in cell adhesion (levels of phosphorylated-ERK are 
enhanced when GnT-V was knockdown)87.   
Taking into consideration that E-Cad dysfunction has a central role in GC 
development and progression, our group has been particularly interested in 
characterizing the role of glycosylation as a key molecular mechanism responsible for 
E-Cad impairment in cancer. In 2009, the group established a clear association 
between E-Cad expression and the upregulation of the GnT-III transcription levels. 
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Furthermore, the decrease of β-1,6 branched structures (catalyzed by GnT-V) was 
noticeable when a lectin specific for this type of structures was used (Biotinylated 
Phaseolus vulgaris Leucoagglutinin [L-PHA]), together with a slight increase of bisecting 
GlcNAc structures (catalyzed by GnT-III). The role of GnT-III in the regulation of E-Cad 
transcription was also studied: using siRNA to silence the gene that codifies for the 
enzyme, the group observed that the level of E-Cad’s mRNA remained unaltered, when 
compared to control cells (non-silenced). Nevertheless, silencing of GnT-III induced a 
significant alteration in the localization of the protein, with E-Cad exhibiting an 
increased cytoplasmic expression, and mislocalization from the membrane. 
Interestingly, the decrease in bisecting GlcNAc structures on E-Cad, detected by 
biotinylated Phaseolus vulgaris Erythroagglutinin (E-PHA - lectin that specifically 
recognize bisecting GlcNAc N-glycans), together with an increase of β-1,6 branched 
glycans, was observed when GnT-III was silenced. In vivo studies were performed in 
diffuse gastric carcinomas, and a significant mislocalization of E-Cad expression was 
observed in tumors, concomitantly with a decrease in bisecting GlcNAc structures and 
higher levels of the branching structures, which validated the in vitro results78. 
Moreover, our group also described the impact of GnT-V activity in E-Cad expression in 
a GC context, and how the absence of this glycosyltransferase (and its product) results 
in a normal distribution of E-Cad in the cell. Also, the importance of specific N-
glycosylation sites was explored, with Asn554 as the selected site that is modified with 
β-1,6 GlcNAc N-glycans structures, thereby assuming a central role in the regulation of 
E-Cad biological functions, namely by interfering with the formation of the E-Cad-
catenins complex27.  
Considering all these results, it seems that there is a mutual regulatory mechanism 
between GnT-III expression and E-Cad-mediated cell-cell adhesion80, and that the 
modification of E-Cad by bisecting GlcNAc N-glycans induces the recruitment of 
catenins to the adherens junction, stabilizing the adhesion complex, and impairing cell 
invasion and metastasis (Figure 8). Accordingly, GnT-V activity in a GC background 
leads to the formation of tri- or tetra-antennary N-glycans that can be extended in a 
wide variety of ways, such as poly-N-acetylactosamine (polyLacNAc) - that is composed 
by a polymer of GlcNAc and Gal monosaccharides - or terminal Neu5Ac residues88. The 
modification of E-Cad with β-1,6 GlcNAc branched structures affects cell-cell adhesion 
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capacity27, by altering the cellular localization of E-Cad and by modifying the cell 
morphology. 
 
1.5 O-mannosylation and E-Cadherin: evidences of a “new” 
player in the adhesion game 
 
Glycoproteins can be modified in a comprehensive variety of ways, such as the 
addition of O-Man monosaccharides to its Ser/Thr residues contributing to their 
stability and biological functions. This O-mannosylation process was thought to be for 
a long time, exclusive of organisms such as Saccharomyces cerevisiae (S. cerevisiae). 
The first time O-mannosylation was described was in 1968 by Sentandreu and 
Northcote, in a glycopeptide that composed the yeast cell wall89. It was only in 1993 
Figure 8 - Alterations in the structure and function of E-Cadherin occur due to the action of GnT-III and GnT-V. 
Enzymatic activity of these glycosyltransferases determines the type of glycans formed, which in turn contributes 
to the promotion or suppression of cancer metastasis (adapted from 
67
). 
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that Strahl-Bolsinger et al. described the gene PMT1, which codifies for the protein 
PMT1 responsible for the initial step of the yeast O-mannosylation process90. The same 
group described a few years later the existence of five additional PMT genes in S. 
cerevisiae, which led them to hypothesize the existence of different protein substrate 
specificities to the different PMTs91.   
In 1996, however, the idea that O-mannosylation was a PTM exclusive from yeast 
was abandoned, as Martín-Blanco and García-Bellido proved the existence of a protein 
in Drosophila melanogaster (D. melanogaster), rotated abdomen (rt), that presented a 
high homology to the S. cerevisiae PMTs92. It is interesting that in Drosophila and in 
Saccharomyces, both rt and PMT, respectively, exhibit important roles in the 
development of the organisms, and that mutations in those genes were potentially 
lethal to the organisms carrying them93.  
In 1999, Jurado et al. identified a putative Human homolog of D. melanogaster’s rt, 
which they named Protein O-mannosyltransferase 1 (POMT1). At that time, they were 
capable of assigning the gene POMT1 to chromosome 9q34.1, and computer 
simulations allowed them to predict that the possible product POMT1 would be a 
transmembrane ER protein94. At that moment, and bearing in mind what was known in 
Drosophila rt, the authors suggested that POMT1 gene mutations might be the 
explanation for some uncharacterized forms of congenital muscular dystrophies. Later, 
the first review of the O-mannosylation process in mammalian organisms was 
published, and the molecular organization of the dystroglycan complex, which is 
composed by α-dystroglycan (α-DG), β-dystroglycan (β-DG), laminin, dystrophin and 
actin, was illustrated for the first time (this complex is of great importance, in a 
biological context, as it is responsible for connecting the ECM and the cellular 
cytoskeleton in skeletal muscle and in Schwann cells). Tamao Endo proposed that O-
mannosylation should has an important role in the basic biological function of α-DG 
(the protein linker between laminin and β-DG) as this glycoprotein was depicted as 
being heavily O-mannosylated56. A lot of work has been done since, especially relating 
O-mannosylation and α-DG in a pathological context, and it is now known that defects 
in this process result in a heterogeneous group of congenital muscular dystrophies 
(CMDs)66,69,95,96. The most severe type of CMD is called the Walker-Warburg syndrome, 
and is essentially characterized by malformations of the brain of the subject, often 
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resulting in a fatal outcome97. The study of CMDs extensively contributed to the 
understanding of the O-mannosylation process. Nevertheless, in 2013 new insights 
about the O-mannosylation process were provided, but this time referring to the 
association between O-mannosylation and cadherins. 
Vester-Christensen et al. modified a cell line (MDA-MB231, which is derived from a 
metastatic site of mammary gland, but has an epithelial morphology) to solely exhibit 
O-Man in its O-glycoproteome98. The fact that the cells were unable to produce 
extended O-GalNAc glycans due to the knockout of COSMC (the chaperone necessary 
for C1GalT1 activity), or to further extend the O-Man monosaccharide due to the 
knockout of POMGNT1, allowed them to look exclusively to the O-mannosylation sites 
existent in all kinds of proteins present in the cell. In order to do that however, they 
first needed to get rid of the N-glycans and the short GalNAc O-glycans present in the 
cell samples, which they did by performing two enrichment steps, using peptide-N-
glycosidase F (PNGase F - to remove the N-glycans) at first, and subsequently using a 
short Concanavalin A (Con A) column (Con A binds α-Man residues, and the O-GalNAc 
glycans are eluted). The analysis of the nanoflow liquid chromatography-mass 
spectrometry results confirmed the existence of a large number of O-Man glycosites 
on α-DG, as it was expected. But the most intriguing fact is, of a total of 52 
glycoproteins identified, 37 of those belonged to the cadherin family of proteins 
(Figure 9), which accounted for approximately 56% of the total number of O-Man 
Figure 9 - Type 1 cadherins were identified by the Clausen group as major carriers of O-mannosyl glycans
84
. 
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glycosites covered on 
those 52 glycoproteins. On 
E-Cad, a type 1 cadherin, 
nine O-mannosylation sites 
were identified, distributed 
between EC2 (3), EC3 (2) 
and EC4 (4), and six sites 
were assigned as putative 
on ECs 2 to 5 (Figure 10).  
Simultaneously, Lommel 
et al. explored the 
importance of O-
mannosylation on E-Cad’s 
biological function99. In 
order to do that they used 
Pomt2 deficient/null mice, 
as the adhesion process 
(and E-Cad in particular) 
has a central role in the 
epithelial to mesenchymal 
transition during 
embryogenesis (in a 
previous study by the same group they demonstrated that the absence of Pomt1 is 
lethal to mouse embryos100). Pomt2+/+ WT and heterozygous Pomt2+/- mice developed 
normally, and in a very similar manner. However, intercrosses between Pomt2+/- mice 
did not generate offspring, as the Pomt2-/- inheritance is lethal even at the embryo 
phase. The authors isolated these embryos and cultivated them in vitro, which allowed 
them to perceive the inability of Pomt2-/- to generate the blastocyst. Additionally, the 
authors used an inhibitor of fungal POMTs rhodanine-3-acetic acid derivative, 
compound 5a (R3A-5a), to selectively inhibit the activity of POMT in Madin-Darby 
canine kidney (MDCK) cells. They observed using an antibody (VIA4-1) specific for an O-
Man linked epitope on α-DG, that 50 µM of R3A-5a was enough to inhibit the O-
Figure 10 - Glycosites identified and predicted on E-Cadherin to date. 
There are a total of 4 N-glycosylation sites, 9 O-mannosylation sites 
(identified in 
84
) and 1 O-GalNAc site, distributed on the protein as 
depicted. A total of 6 O-mannosylation sites were also predicted by the 
Clausen’s group. The glycosylation sites represented were numbered 
considering the propeptide as part of E-Cadherin protein. 
  
22 
mannosylation of α-DG. Having this in mind, the group used R3A-5a when cultivating 
embryos, which arrest their development at the morula to blastocyst transition, with 
the phenotype observed being in everything similar to that of the Pomt2-/- embryos. To 
validate all these results, the authors generated an antibody, T[α1-Man], against a Thr 
O-Man-conjugated epitope, to detect O-mannosylated proteins. The conjugated use of 
T[α1-Man] with the inhibitor R3A-5a and Pomt2-/- mice allowed them to better 
understand the importance of O-mannosylation in cell-cell adhesion, and how that 
influences the development of the embryo. It seemed that, in the R3A-5a-treated 
embryos, the failure in the morula-to-blastocyst transition was due to an abnormal 
formation of cell-cell contacts, namely adherens junctions, which suggested that 
defects in the O-mannosylation of E-Cad could lead to an impairment of cell-cell 
adhesion. In fact, aggregation assays performed using MDCK cells (that express high 
endogenous levels of E-Cad) suggest that O-mannosyl glycans affect cadherin 
mediated cell adhesion, specifically due to the 
high aggregation inhibition observed when using 
the T[α1-Man] antibody and an E-Cad blocking 
antibody (Figure 11).  
The influence of glycosylation for E-Cad 
function has been extensively described, namely 
the influence of two specific glycosyltransferases 
– GnT-III and GnT-V – in the N-glycan landscape 
composing this transmembrane protein. 
Considering this relationship, and taking into 
account the evidences that indicate that E-Cad  
O-mannosylation is essential for its correct 
biological function, the main purpose of this 
project is to assess how O-mannosylation, and its 
interplay with N-glycosylation, regulate E-Cad 
adhesion function, and how this process 
ultimately influences cancer development and 
progression. 
Figure 11 - Slow aggregation assays 
performed using the MDCK cell line using an E-
Cadherin antibody (DECMA-1) and a T[α1-
Man]-specific antibody allowed to understand 
the importance of O-mannosyl glycans in cell-
cell adhesion. EGTA (blocks the Ca
2+
-
dependent cadherin-mediated adhesion), IIH6 
and VIA4-1 (antibodies directed against O-
mannosyl epitopes linked to α-dystroglycan) 
were used as controls
86 
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Aims 
 
The main purpose of this project is to understand the role of O-mannosylation and 
its interplay with N-glycosylation in the modulation of E-Cad functions in tumor 
development and progression.  
In order to accomplish this goal, three specific aims were designed: 
1) To evaluate the O-mannosylation profile in different GC cell line models 
2) To determine the pattern of E-Cad O-mannosylation in a cancer context using in 
vitro cellular models, in order to evaluate the importance of this PTM on E-Cad 
biological function 
3) To characterize the relationship between N-glycosylation and O-mannosylation 
of E-Cad in cancer 
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3.1 Cell lines and cell culture 
 
MKN28 (JCRB0253) and KATO III (ATCC HTB-103) cell lines were cultured at 37ºC in 
an incubator with 5% CO2 in RPMI 1640 medium with Glutamax (Gibco, Invitrogen) 
containing 10% of fetal bovine serum (FBS) (Gibco, Invitrogen), and 1% of the 
antibiotics penicillin/streptomycin (P/S; Invitrogen). 
MKN45 MOCK (empty vector) and MKN45+GnT-V (vector containing N-
acetylglucosaminyltransferase V) cell lines had already been previously stably 
transfected81,101, and were cultured at 37ºC in an incubator with 5% CO2 in RPMI 1640 
medium with Glutamax (Gibco, Invitrogen) containing 10% of FBS (Gibco, Invitrogen), 
1% of the antibiotics P/S (Invitrogen), and 500 µg/mL of the selection antibiotic G418 
(Gibco, Invitrogen). 
 
3.2 Immunofluorescence 
 
Cells from MKN28 and KATO III cell lines were cultured in coverslips in 6 well plates. 
When confluent, the medium was removed and the cells were washed 3 times with 
PBS. After that, the 6 well plates were left on ice as the cells were fixed with methanol 
(previously stored at -20ºC). The cells in the coverslips were then washed 3 times with 
PBS, and subsequently blocked with a BSA 5% solution in PBS for 30 minutes at room 
temperature. After that, the primary mouse monoclonal anti-E-Cad IgG2a antibody 
(clone 36, BD Transduction Laboratories and Cell Signaling), diluted 1:200 in the BSA 
5% solution in PBS, was used to incubate the coverslips for 1 hour at room 
temperature. The coverslips were then washed 3 times with PBS and, from this point 
forward, the procedure was made by avoiding light contact with the samples.  
Incubation with goat Alexa Fluor 488 anti-mouse (1:500 – Invitrogen) was followed by 
6 consecutive washing steps with PBS and by the use of DAPI (1:100) as a nuclear 
marker. A VECTASHIELD mounting medium for immunofluorescence kit was used, and 
the slides were stored at -20ºC and in the dark, until visualization in a Carl Zeiss 
Apotome Axiovert 200 M Fluorescence Microscope. 
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3.3 PNGase F digestion 
 
PNGase F digestion was performed in order to analyze O-linked α-Man glycans 
specifically, avoiding the interaction of the α-Man residues present in the N-linked 
glycans with the lectin used (Con A). PNGase F is an amidase that cleaves that cleaves 
between the innermost GlcNAc and Asn residues of high-Man, hybrid and complex 
oligosaccharides from N-linked glycans in proteins. Total cell lysates (10 to 30 µg) and 
immunoprecipitated samples were combined with denaturing buffer and incubated at 
100ºC for 10 min. Samples were digested overnight (ON) with 1 unit of PNGase F kit 
(New England BioLabs) at 37ºC, 300 rpm. The deglycosylated proteins were loaded 
onto 7,5% SDS-PAGE and immunoblotting with anti E-Cad or Con A lectin. In order to 
control the digestion process, samples were incubated in the same exact conditions 
but without the enzyme.  
 
3.4 Western-Blot and lectin blot analysis  
 
After reaching confluence status, cell cultures were submitted to a washing step 
with autoclaved Phosphate-Buffered Saline (PBS). Cell protein lysates were obtained 
by lysing cell cultures using a cold PBS solution containing 1%(v/v) Triton X-100, 
1%(v/v) NP40, cOmplete (a protease inhibitor cocktail – Roche, 1 tablet/50 mL buffer) 
and a phosphatase inhibitor cocktail (composed by Phenylmethanesulfonyl fluoride 
(PMSF) and Vanadate - Sigma, 1:100 dilution). This lysis buffer was applied on the cell 
monolayers (that were kept on ice) for the period of 15 minutes. After that, the cells 
were scrapped and centrifuged at 13200 rpm for 10 minutes at 4ºC. Prior to use in a 
Western-Blot (WB) or lectin Blot experiment, total protein content of each lysate was 
quantified using a BCA protein assay kit (Pierce). Equal amounts of total cell protein 
lysates (10-35 µg) were submitted to 7,5% SDS-PAGE electrophoresis after the addition 
of Elution buffer (Laemmli 4X, β-mercaptoethanol and Bromophenol Blue) to each 
sample and performing a denaturing step (98ºC, 5 minutes). After electrophoresis, the 
separated proteins were transferred during 2 hours at 50V to nitrocellulose 
membranes (Amersham Biosciences). Ponceau solution was then used for rapid 
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staining of the membranes which were then immediately washed with a PBS-Tween 20 
(PBST; Sigma Aldrich) 0,05% solution or with a Tris-Buffered Saline-Tween 20 (TBST) 
0,05% solution. 
The WB technique was performed using antibodies anti-E-Cad and anti-POMT2. 
After the washing of the Ponceau solution, membranes were blocked in a 5% milk 
solution in PBST 0,05% for E-Cad or in a 5% milk solution in TBST 0,05% for POMT2 for 
1 hour. Afterwards, the mouse monoclonal anti-E-Cad antibody IgG2a (clone 36, BD 
Transduction Laboratories and Cell Signaling; 1:3000 dilution in 5% milk in PBST 0,05%) 
or the anti-POMT2 antibody (loop 5 of the protein, kindly provided by Sabine Strahl’s 
group from University of Heidelberg; 1:500 dilution in 5% milk in TBST 0,05%) were 
used to incubate the membranes ON at 4ºC. At that time, the membranes were 
washed for 30 minutes (changing the solution every 10 minutes) at room temperature 
under agitation conditions. A PBST 0,05% solution was used for the E-Cad membranes, 
whereas in the case of the POMT2  membranes the washing steps were made with 
TBST 0,05% solution. For the E-Cad blot analysis, membranes were incubated for 1 
hour at room temperature under agitation with horseradish peroxidase-linked goat 
anti-mouse IgG secondary antibody (Santa Cruz Biotechnology; 1:2000 dilution in 5% 
milk in PBST). For the POMT2 blot analysis, membranes were incubated for 1 hour at 
room temperature under agitation with horseradish peroxidase-linked goat anti-rabbit 
IgG secondary antibody (Santa Cruz Biotechnology; 1:2000 dilution in 5% milk in TBST). 
A final washing step, similar to what was previously described for each type of 
antibody used, was necessary before performing the detection of the immunoreactive 
bands using ECL reagent (Amersham Biosciences). Loading control analysis was done 
probing blots with anti-actin or anti-tubulin antibodies (Santa Cruz Biotechnology). The 
autoradiography films obtained from each independent experiment were analyzed in a 
densitometer. The bands of interest were quantified and normalized comparing to the 
control that was being used (actin or tubulin).  
In order to perform the lectin blot analysis, membranes were blocked in a 4% 
bovine serum albumin (BSA; Sigma Aldrich) solution in PBST 0,05% for lectin blot ON. 
The lectin blots were then probed with Con A (Vector Laboratories) or L-PHA (Vector 
Laboratories) lectins for 1 hour at room temperature under agitation, and then were 
washed for 30 minutes (changing the solution every 10 minutes) at room temperature 
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under agitation conditions with a PBST 0,05% solution. While Con A recognizes α-Man 
residues present on the sample (either from N-glycans or O-Man glycans), L-PHA reacts 
to the presence of β-1,6 GlcNAc monosaccharides. To visualize the lectin 
immunoreactive bands, Vectorstain ABC kit (Vector Laboratories) was used to incubate 
the membranes for 1 hour at room temperature under agitation. The membranes 
were then washed 3 times (for 30 minutes) at room temperature under agitation 
conditions with a PBST 0,05% solution. The ABC kit is a solution of the complex avidin-
peroxidase that binds with high affinity to the lectins we use as they are biotinylated, 
and biotin interacts with the avidin of the complex. The complexes antigen-lectin-
biotin-avidin-peroxidase were then detected by adding ECL that works as a substrate 
for the peroxidase of the complex. Loading control analysis was done probing blots 
with anti-actin or anti-tubulin antibodies (Santa Cruz Biotechnology). The 
autoradiography films obtained from each independent experiment were analyzed in a 
densitometer.  
3.5 Immunoprecipitation of E-Cadherin 
 
For the IP protocols equal amounts of total protein from each cell lysate (750-1000 
µg) were submitted to a Preclear step with 30 µL of protein G-sepharose beads (Sigma) 
for 1 hour under agitation. Afterwards, the samples were centrifuged (13200 rpm, 5 
minutes, 4ºC) to obtain the supernatant and incubated ON with 1,5 µg of mouse 
monoclonal anti-E-Cad antibody IgG2a (clone 36, BD Transduction Laboratories and 
Cell Signaling) at 4ºC under agitation. Subsequently, the content of each eppendorf 
was incubated with 55 µL of pre-blocked protein G-sepharose beads (with a 1% BSA 
solution in IP buffer – 10%(v/v) lysis buffer and 1%(v/v) NaF 100X (10mM) in PBS) for 2 
hours under agitation. After that, IP buffer was used to wash the beads-antibody-
antigen complexes (3 times, 750 µL). The immune complexes (antibody-antigen) were 
then released by performing a boiling step (5 minutes, 98ºC) in Laemmli sampling 
buffer, and the final samples were subjected to a 7,5% SDS-PAGE electrophoresis. The 
separated proteins were then transferred to a nitrocellulose membrane, and the 
posthumous treatment of the membranes was similar to that of a normal WB or lectin 
blot procedure.  
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Each experiment was reproduced at least 2 times using protein extract from 2 
completely different biological replicas. For all data comparisons, the Student’s T-Test 
was used (two tailed, unequal variance). 
 
 
3.6 Quantitative Real-Time PCR (qRT-PCR) 
 
Total RNA from MKN45 MOCK and MKN45+GnT-V cells was extracted using Tri-
Reagent (Sigma) according to the manufacturer's protocol. 1 μg of total RNA was 
reversed transcribed to single stranded cDNA using Superscript II Reverse 
Transcriptase and random hexamer primers (Invitrogen, Oregon, USA). Quantitative 
Real-Time-PCR (qRT-PCR) was carried out in triplicates for the target genes POMT2 and 
MGAT5, and for the endogenous control GAPDH using as probe sets Hs00203575_m1, 
Hs00159136_m1 (Applied Biosystems, California, USA) and Hs.PT.58.40035104 
(Integrated DNA Technologies, Iowa, USA) respectively. During data analysis, all 
POMT2 and MGAT5 results were normalized against the control GAPDH. GaphPad 
Prism version 6.00 for Windows (GraphPad Software, La Jolla California USA, 
www.graphpad.com) was used to obtain the respective graphs. 
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4.1 MKN28 and KATO III display different morphologies and a 
different E-Cad patterns of expression 
 
In order to acess the role of O-mannosylation in cancer, and particularly on E-Cad, 
we used two GC cell line models known to display different differentiation and 
phenotypical features, namely MKN28 and KATO III. MKN28 was first established from 
a moderately differentiated tubular adenocarcinoma from a 70-year old Asian female 
patient, while KATO III was derived from a poorly differentiated signet-ring cell 
carcinoma at a metastatic site from a 55-year old Asian male patient102,103. MKN28 and 
KATO III GC cell lines showed distinct morphologies and phenotypes when observed 
under bright field and after being cultured under the same conditions. MKN28 GC cells 
display an epithelial-like phenotype, forming a very well defined monolayer of 
cohesive cells that grow in adherence to the flask (Figure 12A). Conversely, KATO III 
gastric carcinoma cells are characterized by being sparse, diffuse and small round-
shaped, while some of those cells present a fibroblastoid-like appearance (Figure 12B).  
The pattern of E-Cad expression in these two GC cell lines was assessed by E-Cad 
immunofluorescence. The results showed that MKN28 displayed a normal pattern of 
expression of E-Cad at the cell membrane (adhesion junctions) (Figure 13A), whereas 
in KATO III we observed a mislocalization of E-Cad to the cytoplasm and we could 
clearly distinguish cells with the fibroblastoid-like phenotype (Figure 13B), showing 
that E-Cad is normally expressed in MKN28 and clearly mislocalized in KATO III.  
Figure 12 - MKN28 and KATO III cells morphological and phenotypical characteristics. (A) MKN28 cell line 
display an epithelial-like phenotype, forming a monolayer of adhesive cells while (B) KATO III cells are smaller 
and round-shaped. 
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4.2 Impact of POMT2 protein expression levels variability in 
the overall O-mannosylation profile and in the E-Cadherin 
O-mannosylation status comparing MKN28 and KATO III 
cell line models 
 
Taking into consideration the differential pattern of E-Cad expression in these two 
GC cell line models, together with previous studies98,99 showing that E-Cad is a target 
of O-mannosylation, we went to access the O-mannosylation profile of E-Cad in these 
two GC contexts. We have evaluated the mRNA expression levels of POMT1 and 
POMT2 (data not shown) in those cell lines, and observed that POMT2’s mRNA was 
expressed almost two times more in MKN28 comparing to KATO III, while POMT1’s 
mRNA was expressed at similar levels. The levels of POMT2 protein expression were 
assessed using total protein lysates from MKN28 and KATO III cell lines. POMT2 is an 
ER transmembrane protein, formed by several helixes and loops. The antibody anti-
POMT2 used targeted the loop5, the largest loop of this protein. The results showed 
that POMT2 is expressed in MKN28 cell line and that it is reduced in KATO III (Figure 
14).  
 
Figure 13 - Immunofluorescence analysis on (A) MKN28 and (B) KATO III cell lines. MKN28 cells demonstrated 
a cell membranous pattern of E-Cadherin expression, whereas KATO III cells displayed a mislocalization of the 
protein. 
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Afterwards, we have evaluated the overall 
O-mannosylation profile of these two different 
gastric cancer cell lines. In order to study the O-
Man glycans accurately, a PNGase F digestion 
step was previously performed to remove all 
the N-linked glycans from all the proteins 
present in the total cell lysates, therefore 
increasing the specificity of Con A towards O-
Man structures. Con A identifies all the α-Man 
residues present in the sample, which means 
that it does not discriminate between O- and N- 
linked α-Man residues, hence the necessity of 
trim all the N-glycans present on the sample. As 
observed in Figure 15 the reactivity against Con 
A in the MKN28 cell line was completely distinct 
from the one obtained for KATO III, with MKN28 presenting higher content of proteins 
with O-mannosyl glycans attached, hence higher Con A reactivity. 
The overall O-mannosylation status of the 
total cell lysates studied pointed to an increase 
in the number of O-mannosyl glycans present in 
the well differentiated MKN28 cell line, which 
led us to address the O-mannosylation profile 
specifically on E-Cad protein. In order to do so, 
we performed E-Cad immunoprecipitation (IP) 
of MKN28 and KATO III cell lines. Then, the E-
Cad IP was digested with PNGase F to remove 
all the N-glycans possibly attached to E-Cad, and 
submitted the samples to a SDS-PAGE and Con 
A WB. We observed that for equal levels of E-
Cad that was immunoprecipitated, the reactivity 
to Con A in the 120 kDa region of E-Cad from 
Figure 14 - Expression levels of POMT2 and 
the overall O-mannosylation profile. (a)  
Analysis by Western blot from total cell lysates 
of MKN28 and KATO III probed with antibodies 
against POMT2 and tubulin (loading control). 
POMT2 is expressed in MKN28 while in KATO III 
no visible band appears. (b) Lectin blot and 
Western blot analysis from digested total cell 
lysates of MKN28 and KATO III cells with Con A 
and the antibody against actin (loading control). 
MKN28 presents higher content in O-mannosyl 
glycans when compared to KATO III, as the lectin 
blot presents higher reactivity in the MKN28 cell 
line lane. 
Figure 15 - The overall O-mannosylation 
profile of MKN28 and KATO III. Lectin blot and 
Western blot analysis from digested total cell 
lysates of MKN28 and KATO III cells with Con A 
and the antibody against actin (loading 
control). MKN28 presents higher content in O-
mannosyl glycans when compared to KATO III, 
as the lectin blot presents higher reactivity in 
the MKN28 cell line lane. 
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MKN28 cell line was much higher (about three times more) when compared to the Con 
A reactivity in E-Cad from KATO III cell line (Figure 16). Therefore, a GC cell line model 
that is moderately differentiated as MKN28 and that presents a normal pattern of E-
Cad distribution at the cell membrane, has increased expression of POMT2 (both at the 
mRNA and the protein levels), as well as a high overall level of O-mannosylation of 
glycoproteins and increased O-Man presence on E-Cad. On the other hand, loss of 
differentiation of a cell line, such as in KATO III, is accompanied by low levels of POMT2 
expression (both at the mRNA and the protein levels) and overall O-mannosylation, as 
well as a low levels of O-Man glycans on E-Cad. 
 
4.3 Relationship between the levels of O-mannose glycans and 
β-1,6 GlcNAc branched N-glycans in different gastric cancer 
cell lines 
 
Our group has demonstrated recently the importance of GnT-V activity in the 
impairment of E-Cad biological function in a GC context, namely due to the addition of 
β-1,6 GlcNAc branched N-glycans specifically on E-Cad-N-glycosylation site 1 (Asn554). 
Furthermore, it was also demonstrated that mutagenesis of this Asn by a glutamine 
Figure 16 - O-mannosylation of E-Cadherin. (A) E-Cadherin was immunoprecipitated from MKN28 and KATO III 
cell lines and the existence of O-mannosyl glycans attached was assessed using simultaneously PNGase F 
digestion and Con A lectin blot. (B) O-mannosyl glycans were only detected on E-Cadherin in MKN28 cell line. 
Level of E-Cadherin was assessed in parallel using the antibody anti-E-Cadherin (clone 36) as a control of the 
immunoprecipitation. The levels of Con A density for MKN28 and KATO III were obtained after normalization to E-
Cadherin. 
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(Gln) residue and silencing of MGAT5 have a protective effect, and prevents 
dysregulation of E-Cad by precluding the attachment of β-1,6 GlcNAc branching N-
glycans at this site27. Taken together, these observations led us to explore the interplay 
between N-glycosylation and O-mannosylation on E-Cad protein in a GC context, 
especially due to the fact that several of those glycosylation sites (N-glycosylation and 
O-mannosylation) are close to each other99.  
We started by comparing the general profiles of O-mannosylation and N-
glycosylation-mediated by GnT-V on both MKN28 and KATO III cell lines. For doing so, 
total cell lysates from these two cell lines were submitted to a lectin blotting using 
either Con A (after removal of N-glycans by PNGase F treatment) or L-PHA lectins, to 
evaluate the O-mannosyl glycans and β-1,6 GlcNAc branching N-glycans, respectively. 
As depicted in Figure 17, 
the overall Con A reactivity 
in MKN28 is high 
comparing with L-PHA 
reactivity, while in KATO III 
we observed a reduced 
reactivity of Con A 
compairing with L-PHA. It is 
interesting that, 
considering the phenotype 
of each cell line, we have a 
higher level of O-Man 
glycans in the well-
differentiated cells MKN28, 
while in the poorly-
differentiated KATO III cells we have higher levels of β-1,6 GlcNAc branching N-glycans. 
Thus, these evidences seem to correlate with the observable phenotype for each cell 
line. 
Afterwards we went to evaluate the levels of O-Man and β-1,6 GlcNAc branched 
structures specifically on E-Cad. We immunoprecipitated E-Cad using total cell lysates 
of MKN28 and KATO III cell lines, with subsequent digestion of the protein content that 
Figure 17 - Levels of O-mannosyl glycans and branched N-glycans in 
total cell lysates of MKN28 and KATO III cell lines. Lectin blots were 
performed in fresh total cell lysates, and actin was used as a loading 
control for both of them. An initial step of digestion was necessary when 
using Con A lectin to assess the O-mannosylation status of the lysates. 
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was immunoprecipitated with PNGase F to remove the N-glycans that were attached 
to E-Cad, and submitted the samples to a WB protocol. We observed that, for equal 
levels of E-Cad that was immunoprecipitated, the level of Con A reactivity on MKN28 E-
Cad band was higher than the levels of L-PHA reactivity. In the case of KATO III, we 
observed that Con A reactivity was decreased on E-Cad, while L-PHA reactivity on E-
Cad band was positive (Figure 18). These differential levels of O-Man and β-1,6 GlcNAc 
branching N-glycans on E-Cad 
seem to correlate with the 
differentiation/phenotype of 
these two GC cell lines and with 
E-Cad cellular localization. 
Moreover, it is interesting that, 
once again, we can correlate a 
more aggressive phenotype 
(KATO III) with loss of O-Man and 
the more differentiated 
phenotype (MKN28) with high 
levels of O-Man glycans on E-
Cad. 
To further explore the relationship between β-1,6 GlcNAc branching N-glycans and 
O-mannosylation, we have used MKN45 MOCK and MKN45+GnT-V cell lines. MKN45 is 
a cell line that was derived in 1976 from a poorly differentiated adenocarcinoma of 
medullary type of a 62-year old female patient. This human gastric adenocarcinoma 
cell line was transfected in a stable way with the empty vector (MKN45 MOCK) or with 
GnT-V (MKN45+GnT-V) by Ihara et al. in 2002101. As GnT-V is the only difference 
between MKN45 MOCK and MKN45+GnT-V, and GnT-V is responsible for the 
production of  β-1,6 GlcNAc branching N-glycans, this makes these two cell lines ideal 
models to study the influence of GnT-V on E-Cad. Here, we intend to use these two cell 
lines to clarify specifically if overexpression of GnT-V and high levels of β-1,6 GlcNAc 
branching N-glycans influence O-mannosylation of E-Cad. 
In order to do so, a RT-PCR protocol was performed to study the expression of 
MGAT5 and POMT2 mRNA in MKN45 MOCK and MKN45+GnT-V cell lines. As the 
Figure 18 - E-Cadherin O-mannosylation and branched N-
glycans content in MKN28 and KATO III cell lines. (A) E-Cadherin 
was immunoprecipitated in order to study its O-mannosylation 
profile and β-1,6 glycans content. Whereas MKN28 E-Cadherin 
presents a huge level of O-mannosyl glycans, it seems that in KATO 
III E-Cadherin is not very O-mannosylated. The levels of L-PHA 
reactivity in both cell lines are very similar to each other.  
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results were normalized against an endogenous control, relative expression levels of 
MGAT5 and POMT2 mRNA could be compared in those cell lines. We confirmed a 30-
fold increase in the expression level of MGAT5 mRNA in the MKN45+GnT-V when 
compared to the MKN45 MOCK cell line (Figure 19 left). When considering POMT2 
expression, we registered a slight increase (about 0,5 times more) in the relative 
expression of its mRNA in MKN45+GnT-V, when compared to MKN45 MOCK cell line 
(Figure 19 right).  
 To continue exploring the interplay between β-1,6 GlcNAc branching N-
glycosylation and O-mannosylation, we performed an IP of E-Cad using total cell 
lysates of these two cell lines, and ran in a 7,5% SDS-PAGE gel. The IP samples were 
used either to evaluate the O-mannosylation status of E-Cad (previously digested to 
remove the N-glycans content) with Con A, or to assess the presence of β-1,6 branched 
N-glycans on E-Cad with L-PHA (Figure 20A). These results showed that MKN45+GnT-V 
cell line presents a significant and consistent decrease in O-mannosyl glycans attached 
to E-Cad when comparing to MKN45 MOCK cell line (almost to half of the structures) 
(Figure 20B). At the same time, MKN45+GnT-V presents around two times more 
reactivity for L-PHA, which means higher levels of β-1,6 GlcNAc branched structured N-
Figure 19 - Relative expression of MGAT5 and POMT2 mRNA in MKN45 MOCK and MKN45+GnT-V cell lines. 
(left) MGAT5 is expressed approximately 30 times more in the MKN45 cell line transfected with GnT-V. (right)  
POMT2 mRNA levels are slightly superior in MKN45+GnT-V when compared to the cells transfected with the 
empty vector (MKN45 MOCK). Results were normalized for GAPDH mRNA expression levels. Relative expression 
of MKN45 MOCK was considered to be 1, and the expression of MKN45+GnT-V was compared in each condition 
(Student’s t-test: * P≤0.05; **** P≤0.001). 
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glycans linked to E-Cad, in contrast to what happens in the MKN45 MOCK cell line 
(Figure 20C).  
  
Figure 20 - E-Cadherin O-mannosylation and branched N-glycans content in MKN45 MOCK and MKN45+GnT-V 
cell lines. (A) E-Cadherin was immunoprecipitated in order to study its O-mannosylation profile and β-1,6 glycans 
content. The presence of GnT-V (MKN45+GnT-V) increases the number of β-1,6 branched N-glycans, when 
comparing to MKN45 MOCK. The level of reactivity of Con A is higher in MKN45 MOCK cells, which indicate a 
greater number of O-mannosyl glycans present on E-Cadherin, when compared to MKN45+GnT-V. (B and C) The 
levels of Con A and L-PHA densities for MKN45 MOCK and MKN45+GnT-V were obtained after normalization to E-
Cadherin, being expressed as the fold change, compared with the association level of the same lectin with E-
cadherin in MKN45 MOCK cells, which was taken as 1 (Student’s t-test: **P≤0.01; **** P≤0.001). 
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Discussion and Conclusions 
 
The vast majority of cancer types present an aberrant glycosylation profile. In 
recent years, researchers have been paying more attention to the role of glycans in a 
cancer context due to the fact that many glycosyl epitopes are also tumor-associated 
antigens. The fact is glycobiology has been contributing to decipher important cancer 
mechanisms that may be applied to improve cancer diagnosis and in the development 
of new therapeutic strategies51,72,104,105.  
In a normal cellular environment, a set of glycosyltransferases regulates the 
synthesis of a group of specific glycans that can be attached to the proteins, whereas 
in a tumor microenvironment glycoproteins can be produced with a set of cancer-
specific glycans, in a cell and tissue specific manner. For instance GnT-III and GnT-V act 
enzymatically on the same core structure linked to a protein [Asn]-
GlcNAc2Man3(GlcNAc)2
80. However, while GnT-III is responsible for the addition of a 
bisecting GlcNAc and suppression of tumor metastasis106, GnT-V adds the same 
monosaccharide but forming a β-1,6 GlcNAc branching structured glycan, described to 
have a huge importance in tumor progression and metastatic process107,108. It is also 
known that action of GnT-III always precedes that of GnT-V, and that the product that 
is formed cannot be then modified by a β-1,6 branching GlcNAc81. The expression 
levels of these glycosyltransferases have an impact on several cellular mechanisms, 
namely cell-cell adhesion80,83,109.  
The adherens junctions are essential to maintain tissue architecture and integrity 
through an array of intercellular signaling pathways110,111. E-Cad is one of the most 
important components of the adherens junctions, being composed by a 
transmembrane domain, a cytoplasmic domain, and a large extracellular domain that 
comprises the five cadherin repeats - ECs 1 to 521. E-Cad is also a glycoprotein modified 
by N- and O-glycans that are important for its folding, expression and 
functions25,26,98,99. Dysfunction of E-Cad has, as expected, tremendous deleterious 
effects in cell biology, and has been considered as one of the key factors for cancer 
development and progression42,43,112. Throughout the years, our group was able to 
characterize in detail the role of alterations in the N-glycosylation profile of E-Cad, and 
how they influence the attainment of a malignant phenotype27,40,51,78,108,113, backing up 
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the notion that the differential occupation of the four N-glycosylation sites available on 
E-Cad, individually or simultaneously, determines the modulation of E-Cad expression 
and its biological activity and function. Recently, O-mannosylation was related for the 
first time to cadherins, specifically E-Cad, by two individual laboratories: the 
Copenhagen Center for Glycomics discovered nine O-mannosylation sites available in 
E-Cad98, while the role of O-Man on E-Cad biological function was reported at the 
Heidelberg University99.  
Taking these observations altogether, the present study intends to specifically 
define how the O-mannosylation profile of E-Cad has an impact on its biological 
function, in a cancer context. Moreover, the relation between N-glycosylation and O-
mannosylation of E-Cad, in the same pathological context, was also explored.  
We studied two different GC cell lines that display different morphological and 
phenotypical features, MKN28 and KATO III cell lines. MKN28 cell line was established 
from a moderately differentiated tubular adenocarcinoma that grows in a more 
epithelial-like fashion, while KATO III cell line is derived from a poorly differentiated 
advanced gastric carcinoma. Accordingly, the pattern of expression of E-Cad in each 
cell line model is distinguishable, with MKN28 displaying a well-defined membranar 
pattern of E-Cad expression and KATO III exhibiting a mislocalization of E-Cad (Figures 
12 and 13). Using these two different GC cell lines (well-differentiated, with normal E-
Cad expression versus poorly-differentiated with mislocalization of E-Cad) as models 
we intend to explore the overall and E-Cad specific O-mannosylation profile of each 
cell line, and the interplay between O-mannosylation and N-glycosylation. We 
correlated both the POMT2 expression and the overall O-mannosylation profile of each 
cell line. The WB for POMT2 shows a strong relationship with the lectin blot for O-Man 
glycans, with MKN28 presenting higher expression of POMT2 and more reactivity for 
the Con A lectin when comparing to KATO III (Figures 14 and 15). In fact, in KATO III a 
faint reactivity to POMT2 was detected using the antibody for the loop5 of the protein, 
which may potentially indicate its incorrect expression. Afterwards, we went to assess 
the pattern of O-Man on E-Cad in MKN28 and KATO III; so we immunoprecipitated the 
protein in order to proceed to an analysis of its O-mannosyl glycans content. PNGase F 
digestion of the immunoprecipitates was needed to trim all the N-glycans existent on 
E-Cad, and the lectin blot with Con A allowed us to detect specifically α-O-Man 
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monosaccharides. Figure 16 reveals that E-Cad from MKN28 presents a high content in 
O-Man while poor O-mannosylation is detected on E-Cad from KATO III, which seems 
to indicate that E-Cad loses its O-Man content in a more aggressive phenotype.  
Summing up the results presented so far, and taking into account the recognized 
importance of correct E-Cad O-mannosylation in the cell-cell adhesion process99, we 
can correlate the expression of POMT2 with an higher level of O-mannosylated glycans 
in glycoproteins in general, but also in the specific case of E-Cad. These results seem to 
be in accordance to what was observed at Heidelberg University, as an increase in 
adherence of cells (MKN28 cell line) is accompanied by an enhancement in POMT2 
expression and O-mannosylated glycoproteins. On the case of the more aggressive 
phenotype of KATO III, we can correlate it with the absence of POMT2 and of O-
mannosylation of E-Cad. 
The next step was to associate the O-mannosylation and the β-1,6 branched N-
glycosylation levels in both GC cell line models, using a lectin blot strategy. We 
observed a distinguishable reactivity of Con A and L-PHA in MKN28 and KATO III, with 
the latter presenting a huge distribution of proteins with branched N-glycans and 
lower levels of O-mannosyl glycans. Conversely, MKN28 presents a high content of 
proteins that are O-mannosylated, and lower levels of β-1,6 GlcNAc branched N-
glycans. We have also shown that MKN28 presents more O-Man content than KATO III, 
which made us realize that the overall distribution of O-Man and β-1,6 N-glycans can 
be inversely correlated, and that the expression of higher contents of O-Man also 
corresponds to a more epithelial-like phenotype (Figure 17). IP of E-Cad would provide 
us the perfect assessment of the overall glycosylation profile of the protein. In several 
experiments, we have evaluated the O-Man distribution and the β-1,6 branched N-
glycans presence on E-Cad individually. The O-Man content was almost absent in E-Cad 
from KATO III lysates, but there is a high reactivity towards L-PHA, indicating the 
presence of a higher content of β-1,6 branching structures on E-Cad. On the other 
hand, E-Cad from MKN28 exhibits a huge reactivity towards Con A, pointing to the 
presence of several O-Man glycans, while L-PHA reactivity is lower, indicating the 
presence of less β-1,6 GlcNAc branching structures on E-Cad (Figure 18). 
To further validate these results relating the relationship between O-mannosylation 
and N-glycosylation, we have used two other cancer cell line models, MKN45 MOCK 
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and MKN45+GnT-V, as they have already been widely used by our group as important 
models for studying the influence of β-1,6 GlcNAc glycans on E-Cad in GC108. To 
confirm the overexpression of GnT-V in MKN45+GnT-V, we performed a RT-PCR 
protocol for the MGAT5 mRNA of MKN45 MOCK and MKN45+GnT-V cell lines. As 
previously demonstrated108, the latter presents an almost 30-fold increase in mRNA 
relative expression when compared to the MOCK cells (Figure 19 – left). We also 
analyzed POMT2 mRNA expression using the same technique, and concluded that 
there is a slight increase in the MKN45+GnT-V cell line (Figure 19 – right). Afterwards, 
we immunoprecipitated E-Cad from both cell lines to evaluate specifically the O-Man 
and β-1,6 branched N-glycans content. Considering MKN45 MOCK we have a higher 
content of O-Man residues attached to E-Cad, and a smaller reactivity to L-PHA that 
indicates reduced amounts of β-1,6 branched N-glycans linked to E-Cad in this cell line 
when compared to MKN45+GnT-V (Figure 20). In light to what was described by our 
group the results suggest that an increase in O-Man content and the absence of 
branched N-glycans attached to E-Cad leads to a more stable phenotype108. However, 
the role of GnT-III in this conundrum remains to be clarified, as it would be interesting 
to assess if we would get an increase in O-mannosylation of E-Cad by the insertion of 
GnT-III or, on the other hand, the occupation of the N-glycosylation sites by bisecting 
N-glycans could lead to a halt in the O-mannosylation process.  
Overall, it seems that POMT2 protein has in fact a role in E-Cad O-mannosylation in 
cancer and in the modulation of its functions67,114. Interestingly, the cancer cell line 
with a more aggressive phenotype (KATO III) loses O-Man glycans attached to E-Cad, 
which is associated with its cellular mislocalization and in line to what was presented 
by Sabine Strahl’s group regarding the importance of O-mannosylation of E-Cad for 
cell-cell adhesion99. The connection between O-mannosylation and N-glycosylation is 
also an innovative finding particularly in a GC context. The presence of O-Man on E-
Cad appears to be inversely related with the presence of β-1,6 branched N-glycans, 
and the aggressiveness of a cancer might be determined by the balance of these two 
types of glycosylation (Figure 21). 
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[These results are a part of a more comprehensive project. Part of these results was 
included in a manuscript that will be submitted for publication.] 
 
 
    
Figure 21 - Proposed model for the interplay between O-mannosylation and N-glycosylation. In a normal 
epithelial cell context, more O-mannosyl glycans are linked to E-Cad, as the protein does not have such bulky N-
glycans due to the absence of GnT-V activity. On the other hand, in an adenocarcinoma cell context, GnT-V 
activity leads to the formation of huge complex N-glycan structures, which precludes the attachment of so many 
O-Man residues, contributing to a decrease in cell-cell adhesion and to a decreased stability of the E-Cad-catenins 
complex. 
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Future perspectives 
 
Glycobiology plays a huge role in cancer, as further corroborated by this study. The 
prominence of N-glycosylation in tumor cell-cell adhesion, specifically the importance 
of modifications of E-Cad N-glycans structure, has already been extensively 
studied12,27,78,108. The novelty surrounding O-mannosylation allows researchers to 
hypothesize new ways of how to address old problems. During the course of this 
project, we intended to assess an unexplored scientific issue on the role of O-
mannosylation in GC, focusing on the modulation of the functions of E-Cad. Indeed, we 
were able to establish a new field of expertise relating glycobiology and cancer, as no 
one has ever described O-mannosylation mechanisms in this pathological context. 
Moreover, E-Cad O-mannosylation profile, and the interplay with N-glycosylation, was 
also studied in different cancer contexts. Some of the mechanisms behind this 
relationship however remain unraveled. 
When the Copenhagen group proposed that E-Cad could be strongly O-
mannosylated, they did it using a SimpleCell technique that allowed them to look 
solely to O-Man monosaccharides present on glycoproteins without further 
extension98. However, in a cellular environment we do not know what actually 
happens in terms of O-mannosylation proteins such as E-Cad. In this case, it is of the 
utmost importance to determine the preferential sites of O-mannosylation of E-Cad, 
because maybe between the 9 identified positions and the 6 that were predicted we 
can have dominance in the locale of O-mannosylation, as verified for N-glycosylation27. 
The fact is, O-mannosyl glycans can exist in those positions, but, in a cell that 
composes an organ we do not know how many of these glycans we have, where, and 
how they modify the E-Cad biological function. 
It is also important to know how O-mannosylation and N-glycosylation of E-Cad are 
specifically connected, as several of these sites are close to one another as depicted in 
Figure 10. Does, for instance, any N-glycan (high-mannose content, hybrid or complex) 
that occupies Asn554 affect the attachment of O-Man to Thr505? We have proven 
here that the introduction of a glycosyltransferase (GnT-V) that produces branching N-
glycans in a cell line actually induces a decrease in the number of O-Man 
monosaccharides on E-Cad. But what is the mechanism behind this? Could it be just 
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the occupancy of the N-glycosylation sites, or to a regulation of the levels of POMT2 
protein or other glycosyltransferases produced? It is also very important to explore the 
machinery that regulates POMT2 expression (as well as other POMTs) and if it is in fact 
this protein the sole responsible for the O-mannosylation of E-Cad. 
While studying, we have actually started to paying more interest to POMT2 when 
compared to POMT1, as we performed an RT-PCR to evaluate the mRNA levels of 
POMT1 and POMT2 genes and realized that, when comparing MKN28 and KATO III cell 
lines, POMT2 mRNA was more expressed in MKN28, while POMT1 showed no 
significant differences amongst the two cell lines (results not shown). We chose to 
specifically learn about the role of POMT2 protein on O-mannosylation in GC, but we 
obtained some intriguing results (Figure 15) that make us question the relative 
importance of each mannosyltransferase to the overall process, and if there are other 
redundancies unknown, such as other POMTs not yet described.  
Due to the huge importance of E-Cad on a GC context, all the knowledge relating its 
glycans content has enormous impact, especially if we can find a distinguishable 
pattern between a normal situation and a disease state, envisioning clinical 
applications.   
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